PharmaShots | Incisive News in 3 Shots

Subscribe Now

NK Cell Therapies

Intellia Signs a License and Collaboration Agreement with ONK to Advance Allogeneic CRISPR-Edited NK Cell Therapies for Cancer

Intellia Signs a License and Collaboration Agreement with ONK to Advance Allogeneic CRISPR-Edited NK Cell Therapies for Cancer

February 16, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us